Heath-Chiozzi Margo
Known title: SVP of Regulatory AffairsCIK: 0001718112
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 6,289 | $57K | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 58,369 | $606K | 6/3/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 58,369 | $2.0M | 6/3/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 29,068 | $81K | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 2,043 | $18K | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 2,608 | $27K | 5/30/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 38,719 | $1.3M | 5/30/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 600 | $2K | 12/8/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 600 | $24K | 12/8/2021 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 600 | $2K | 11/1/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 600 | $25K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.